27.05.2015 • NewsDede WillamsPeopleLa Seda de Barcelona

Ex-La Seda CEO Gets off Light in Embezzlement Case

Due to successful plea bargaining, two executives of former Spanish PET producer La Seda de Barcelona, now in liquidation - including former CEO Rafael Español - have escaped severe penalties for embezzlement of company funds and may possibly avoid jail time altogether, Spanish reports say.

Español has pleaded guilty to misappropriation of funds, a charge that carries a penalty of 11 months and 15 days. The prosecutor in the case being heard a Barcelona court had asked for a sentence of 27 years and six months.

The ex-CEO has agreed to pay a fine of €702 million, which is in part restitution for tax evasion.

Español and another manager, Antonio Comadrán, are said to have admitted diverting €12.2 million from La Seda's corporate coffers to other firms in a web of fictitious enterprises.

Six other men involved with companies in the alleged extortion network have accepted penalties of €1,500 and received sentences of seven months in prison. Other cases are still pending against principals of the erstwhile PET market leader, including Español.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.